Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $349,625.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 12,500 shares of Bicara Therapeutics stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total transaction of $349,625.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares in the company, valued at approximately $3,632,044.35. This trade represents a 8.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, July 8th, Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00.
• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.42, for a total transaction of $187,864.00.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock opened at $24.28 on Friday. The company has a 50 day moving average price of $26.15 and a 200 day moving average price of $21.80. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -7.83 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting the consensus estimate of ($0.82). Equities analysts forecast that Bicara Therapeutics Inc. will post -3.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on BCAX. Mizuho lifted their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday. Wedbush increased their price objective on Bicara Therapeutics from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. BTIG Research lifted their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Morgan Stanley upped their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.73.

Institutional Investors Weigh In On Bicara Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics during the 4th quarter valued at $45,000. Legal & General Group Plc increased its stake in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter. Larson Financial Group LLC raised its holdings in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after acquiring an additional 3,595 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its position in Bicara Therapeutics by 385.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock valued at $97,000 after purchasing an additional 4,585 shares during the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.